Does the media refer more to OLMA or ZLAB?

In the previous week, Zai Lab had 3 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 4 mentions for Zai Lab and 1 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 1.73 beat Zai Lab's score of -0.33 indicating that Olema Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Olema Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Zai Lab 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts recommend GMTX or OLMA?

Olema Pharmaceuticals has a consensus target price of $40.60, suggesting a potential upside of 390.16%. Given Olema Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Olema Pharmaceuticals is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Olema Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.77

Which has preferable earnings and valuation, GMTX or OLMA?

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gemini Therapeutics N/A N/A -$71.87M -$1.00 N/A Olema Pharmaceuticals N/A N/A -$162.45M -$2.12 N/A

Is GMTX or OLMA more profitable?

Gemini Therapeutics' return on equity of -38.78% beat Olema Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Gemini Therapeutics N/A -38.78% -35.88% Olema Pharmaceuticals N/A -48.26% -43.04%

Does the media prefer PGEN or OLMA?

In the previous week, Precigen had 13 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 14 mentions for Precigen and 1 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 1.73 beat Precigen's score of 0.69 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precigen 3 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Olema Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer OLMA or NAMS?

In the previous week, NewAmsterdam Pharma had 5 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 6 mentions for NewAmsterdam Pharma and 1 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 1.73 beat NewAmsterdam Pharma's score of 0.14 indicating that Olema Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Olema Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive NewAmsterdam Pharma 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, OLMA or IRON?

Disc Medicine is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Olema Pharmaceuticals N/A N/A -$162.45M -$2.12 N/A Disc Medicine N/A N/A -$212.18M -$6.58 N/A

Is OLMA or IRON more profitable?

Disc Medicine's return on equity of -37.17% beat Olema Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Olema Pharmaceuticals N/A -48.26% -43.04% Disc Medicine N/A -37.17% -33.65%

Does the media prefer OLMA or IRON?

In the previous week, Disc Medicine had 4 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 5 mentions for Disc Medicine and 1 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 1.73 beat Disc Medicine's score of 0.41 indicating that Olema Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Olema Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Disc Medicine 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Olema Pharmaceuticals (OLMA) Competitors

$8.22 -0.05 (-0.57%)

Closing price 03:59 PM Eastern

Extended Trading

$8.23 +0.01 (+0.09%)

As of 04:01 PM Eastern

Compare

OLMA vs. ZLAB, GMTX, PGEN, NAMS, and IRON

Should you buy Olema Pharmaceuticals stock or one of its competitors? Olema Pharmaceuticals's main competitors and comparable companies include Zai Lab (ZLAB), Gemini Therapeutics (GMTX), Precigen (PGEN), NewAmsterdam Pharma (NAMS), and Disc Medicine (IRON). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Olema Pharmaceuticals compare to Zai Lab?

Olema Pharmaceuticals (NASDAQ:OLMA) and Zai Lab (NASDAQ:ZLAB) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

In the previous week, Zai Lab had 3 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 4 mentions for Zai Lab and 1 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 1.73 beat Zai Lab's score of -0.33 indicating that Olema Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Olema Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Zai Lab	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

91.8% of Olema Pharmaceuticals shares are held by institutional investors. Comparatively, 41.7% of Zai Lab shares are held by institutional investors. 12.6% of Olema Pharmaceuticals shares are held by insiders. Comparatively, 4.9% of Zai Lab shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Olema Pharmaceuticals has a net margin of 0.00% compared to Zai Lab's net margin of -41.86%. Zai Lab's return on equity of -27.43% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-48.26%	-43.04%
Zai Lab	-41.86%	-27.43%	-16.72%

Olema Pharmaceuticals currently has a consensus target price of $40.60, suggesting a potential upside of 390.16%. Zai Lab has a consensus target price of $37.25, suggesting a potential upside of 52.64%. Given Olema Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Zai Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Olema Pharmaceuticals has higher earnings, but lower revenue than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.12	N/A
Zai Lab	$460.16M	6.03	-$175.54M	-$1.71	N/A

Olema Pharmaceuticals has a beta of 2, suggesting that its share price is 100% more volatile than the broader market. Comparatively, Zai Lab has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market.

Summary

Olema Pharmaceuticals beats Zai Lab on 10 of the 16 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to Gemini Therapeutics?

Gemini Therapeutics (NASDAQ:GMTX) and Olema Pharmaceuticals (NASDAQ:OLMA) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

75.4% of Gemini Therapeutics shares are held by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are held by institutional investors. 12.9% of Gemini Therapeutics shares are held by insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Gemini Therapeutics' return on equity of -38.78% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Olema Pharmaceuticals	N/A	-48.26%	-43.04%

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.12	N/A

In the previous week, Olema Pharmaceuticals had 1 more articles in the media than Gemini Therapeutics. MarketBeat recorded 1 mentions for Olema Pharmaceuticals and 0 mentions for Gemini Therapeutics. Olema Pharmaceuticals' average media sentiment score of 1.73 beat Gemini Therapeutics' score of 0.00 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Gemini Therapeutics	Neutral
Olema Pharmaceuticals	Very Positive

Gemini Therapeutics has a beta of -0.12, suggesting that its stock price is 112% less volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 2, suggesting that its stock price is 100% more volatile than the broader market.

Olema Pharmaceuticals has a consensus target price of $40.60, suggesting a potential upside of 390.16%. Given Olema Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Olema Pharmaceuticals is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Olema Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Summary

Olema Pharmaceuticals beats Gemini Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to Precigen?

Precigen (NASDAQ:PGEN) and Olema Pharmaceuticals (NASDAQ:OLMA) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership and analyst recommendations.

Olema Pharmaceuticals has a net margin of 0.00% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precigen	-183.98%	423.75%	84.39%
Olema Pharmaceuticals	N/A	-48.26%	-43.04%

Precigen currently has a consensus price target of $13.67, suggesting a potential upside of 64.76%. Olema Pharmaceuticals has a consensus price target of $40.60, suggesting a potential upside of 390.16%. Given Olema Pharmaceuticals' higher probable upside, analysts plainly believe Olema Pharmaceuticals is more favorable than Precigen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Olema Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Precigen has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 2, suggesting that its stock price is 100% more volatile than the broader market.

In the previous week, Precigen had 13 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 14 mentions for Precigen and 1 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 1.73 beat Precigen's score of 0.69 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precigen	3 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Olema Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

33.5% of Precigen shares are owned by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 41.4% of Precigen shares are owned by insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Olema Pharmaceuticals has lower revenue, but higher earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precigen	$9.68M	305.50	-$250.64M	-$1.04	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.12	N/A

Summary

Precigen and Olema Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to NewAmsterdam Pharma?

Olema Pharmaceuticals (NASDAQ:OLMA) and NewAmsterdam Pharma (NASDAQ:NAMS) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

Olema Pharmaceuticals presently has a consensus target price of $40.60, suggesting a potential upside of 390.16%. NewAmsterdam Pharma has a consensus target price of $49.73, suggesting a potential upside of 113.01%. Given Olema Pharmaceuticals' higher possible upside, analysts clearly believe Olema Pharmaceuticals is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

In the previous week, NewAmsterdam Pharma had 5 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 6 mentions for NewAmsterdam Pharma and 1 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 1.73 beat NewAmsterdam Pharma's score of 0.14 indicating that Olema Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Olema Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
NewAmsterdam Pharma	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

91.8% of Olema Pharmaceuticals shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 12.6% of Olema Pharmaceuticals shares are owned by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Olema Pharmaceuticals has a beta of 2, suggesting that its share price is 100% more volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.1, suggesting that its share price is 90% less volatile than the broader market.

Olema Pharmaceuticals has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -3,644.21%. NewAmsterdam Pharma's return on equity of -34.81% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-48.26%	-43.04%
NewAmsterdam Pharma	-3,644.21%	-34.81%	-31.50%

Olema Pharmaceuticals has higher earnings, but lower revenue than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.12	N/A
NewAmsterdam Pharma	$22.50M	124.03	-$203.82M	-$2.16	N/A

Summary

Olema Pharmaceuticals beats NewAmsterdam Pharma on 9 of the 16 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to Disc Medicine?

Olema Pharmaceuticals (NASDAQ:OLMA) and Disc Medicine (NASDAQ:IRON) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

In the previous week, Disc Medicine had 4 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 5 mentions for Disc Medicine and 1 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 1.73 beat Disc Medicine's score of 0.41 indicating that Olema Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Olema Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Disc Medicine	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Disc Medicine is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.12	N/A
Disc Medicine	N/A	N/A	-$212.18M	-$6.58	N/A

Olema Pharmaceuticals has a beta of 2, suggesting that its share price is 100% more volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

91.8% of Olema Pharmaceuticals shares are owned by institutional investors. Comparatively, 83.7% of Disc Medicine shares are owned by institutional investors. 12.6% of Olema Pharmaceuticals shares are owned by company insiders. Comparatively, 3.8% of Disc Medicine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Disc Medicine's return on equity of -37.17% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-48.26%	-43.04%
Disc Medicine	N/A	-37.17%	-33.65%

Olema Pharmaceuticals presently has a consensus target price of $40.60, suggesting a potential upside of 390.16%. Disc Medicine has a consensus target price of $110.18, suggesting a potential upside of 70.43%. Given Olema Pharmaceuticals' higher possible upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Summary

Olema Pharmaceuticals beats Disc Medicine on 8 of the 11 factors compared between the two stocks.

Get Olema Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OLMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OLMA vs. The Competition

Export

Metric	Olema Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$713.56M	$3.83B	$7.11B	$13.24B
Dividend Yield	N/A	3.64%	2.53%	15.88%
P/E Ratio	-3.85	13.45	274.71	26.06
Price / Sales	N/A	1,284.75	600.46	89.74
Price / Cash	N/A	121.76	77.38	51.25
Price / Book	1.39	16.62	10.93	6.32
Net Income	-$162.45M	-$22.67M	$3.50B	$361.55M
7 Day Performance	-6.85%	-3.21%	-2.21%	-1.67%
1 Month Performance	-24.74%	-10.88%	-6.45%	-3.94%
1 Year Performance	-26.83%	21.05%	8.70%	2.75%

Olema Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OLMA Olema Pharmaceuticals	2.7721 of 5 stars	$8.22 -0.6%	$40.60 +393.7%	-25.1%	$719.51M	N/A	N/A	150	Positive News
ZLAB Zai Lab	1.8364 of 5 stars	$25.86 +0.7%	$37.25 +44.0%	-26.0%	$2.95B	$460.16M	N/A	1,784	Gap Down
GMTX Gemini Therapeutics	N/A	$64.92 -0.5%	N/A	-0.9%	$2.81B	N/A	N/A	30	High Trading Volume
PGEN Precigen	3.8959 of 5 stars	$7.86 +0.6%	$13.67 +74.0%	+145.8%	$2.81B	$9.68M	N/A	47
NAMS NewAmsterdam Pharma	3.6011 of 5 stars	$23.40 -0.8%	$49.73 +112.5%	-17.7%	$2.80B	$22.50M	N/A	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OLMA) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Olema Pharmaceuticals (OLMA) Competitors

OLMA vs. ZLAB, GMTX, PGEN, NAMS, and IRON

How does Olema Pharmaceuticals compare to Zai Lab?

Summary

How does Olema Pharmaceuticals compare to Gemini Therapeutics?

Summary

How does Olema Pharmaceuticals compare to Precigen?

Summary

How does Olema Pharmaceuticals compare to NewAmsterdam Pharma?

Summary

How does Olema Pharmaceuticals compare to Disc Medicine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OLMA vs. The Competition

Olema Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Olema Pharmaceuticals (OLMA) Competitors

OLMA vs. ZLAB, GMTX, PGEN, NAMS, and IRON

How does Olema Pharmaceuticals compare to Zai Lab?

Does the media refer more to OLMA or ZLAB?

Do institutionals & insiders have more ownership in OLMA or ZLAB?

Is OLMA or ZLAB more profitable?

Do analysts rate OLMA or ZLAB?

Which has better earnings & valuation, OLMA or ZLAB?

Which has more risk and volatility, OLMA or ZLAB?

Summary

How does Olema Pharmaceuticals compare to Gemini Therapeutics?

Do insiders and institutionals hold more shares of GMTX or OLMA?

Is GMTX or OLMA more profitable?

Which has preferable earnings and valuation, GMTX or OLMA?

Does the media refer more to GMTX or OLMA?

Which has more volatility & risk, GMTX or OLMA?

Do analysts recommend GMTX or OLMA?

Summary

How does Olema Pharmaceuticals compare to Precigen?

Is PGEN or OLMA more profitable?

Do analysts prefer PGEN or OLMA?

Which has more risk & volatility, PGEN or OLMA?

Does the media prefer PGEN or OLMA?

Do institutionals & insiders hold more shares of PGEN or OLMA?

Which has better earnings and valuation, PGEN or OLMA?

Summary

How does Olema Pharmaceuticals compare to NewAmsterdam Pharma?

Do analysts prefer OLMA or NAMS?

Does the media prefer OLMA or NAMS?

Do institutionals and insiders hold more shares of OLMA or NAMS?

Which has more volatility & risk, OLMA or NAMS?

Is OLMA or NAMS more profitable?

Which has higher valuation and earnings, OLMA or NAMS?

Summary

How does Olema Pharmaceuticals compare to Disc Medicine?

Does the media prefer OLMA or IRON?

Which has higher valuation and earnings, OLMA or IRON?

Which has more volatility & risk, OLMA or IRON?

Do institutionals and insiders hold more shares of OLMA or IRON?

Is OLMA or IRON more profitable?

Do analysts prefer OLMA or IRON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OLMA vs. The Competition

Olema Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools